Andrew von Eschenbach
From Wikipedia, the free encyclopedia
Andrew C. von Eschenbach (born October 30, 1941 in Philadelphia, Pennsylvania) is the current Commissioner of the United States Food and Drug Administration. He became acting Commissioner on September 26, 2005, after the resignation of his predecessor Lester Crawford, and was confirmed as Commissioner by the Senate on December 7, 2006.[1][2] He was previously the 12th director of the National Cancer Institute.
After graduating from St. Joseph's Preparatory School, Von Eschenbach received his bachelor of science from St. Joseph's University in 1963 and his MD from Georgetown University School of Medicine in 1967. He did residencies at Pennsylvania Hospital in general surgery and urology and taught urology at the University of Pennsylvania School of Medicine. He served in the US Navy Medical Corps with the rank of lieutenant commander from 1968 to 1971.
In 1976, von Eschenbach began his long association with The University of Texas M. D. Anderson Cancer Center, beginning as a urologic oncology fellow and becoming chair of the department of urology in 1983. He was founding director of the Prostate Cancer Research Program in 1996, director of the Genitourinary Cancer Center, and held the Roy M. and Phyllis Gough Huffington Clinical Research Distinguished Chair in Urologic Oncology. Driven by his father's prostate cancer, he specialized in the disease. That commitment, however, has been questioned following the FDA's failure to approve Provenge for the treatment of prostate cancer (against the recommendation of an independent advisory committee).
Von Eschenbach was president-elect of the American Cancer Society when he was selected by President George W. Bush to head the NCI in December 2001. As director of the NCI he announced in 2003 that his organization's goal was to "eliminate suffering and death" caused by cancer by the year 2015.
In 2006, Time named him as one of the Time 100 "People Who Shape Our World", writing that as head of the FDA, which "wields enormous influence on American lives", von Eschenbach "could make a signal contribution to the public's health" by focusing on issues of diet and obesity in addition to drugs and disease.
On August 1, 2006, Senators Clinton and Cantwell announced they would block his nomination to be the permanent FDA commissioner because of his department's failure to act on the application by Barr Pharmaceuticals to sell Plan B over-the-counter. They utimately voted for his nomination.[2]
[edit] Notes
- ^ U.S. Congress (7 December 2006). "Executive Session". Congressional Record 152 (134): S11404–29, S11447–51.
- ^ a b Senate Vote No. 274
[edit] References
- "Andrew von Eschenbach." Biography Resource Center Online. Gale, 2006.
[edit] External links
- Food and Drug Administration biography
- National Cancer Institute biography
- "Biosketch for Dr. Andrew von Eschenbach", NCI BenchMarks, vol. 2 no. 1, January 22, 2002.
- "Andrew von Eschenbach: Entering the Fray at the FDA", Michael Jacobson, Time, Apr. 30, 2006.
|
|||||||
